CN Bio Partners with Pharmaron to Advance Organ-on-a-Chip Integration

• CN Bio and Pharmaron have announced a strategic partnership to validate and integrate Organ-on-a-Chip (OOC) technology into drug discovery and development workflows.

• The agreement includes global installation of PhysioMimix instruments and collaborative development of new applications.

CN Bio has announced a strategic partnership with Pharmaron, aimed at validating and deploying its PhysioMimix Organ-on-a-Chip (OOC) platform across Pharmaron’s global R&D sites. The agreement also includes plans to co-develop new applications to support unmet needs in drug discovery and development.

In the first phase, Pharmaron will evaluate the use of the PhysioMimix system in established areas such as disease modelling, toxicity studies, and ADME (absorption, distribution, metabolism, and excretion) testing. Upon successful validation, both companies intend to adopt the platform more broadly and jointly create innovative applications to extend OOC capabilities.

The partnership will see CN Bio install PhysioMimix instruments across Pharmaron’s international facilities. Pharmaron, a global R&D service provider supporting drug discovery through to clinical development, aims to integrate the technology into its service offering to address evolving research demands.

Dr Paul Brooks, CEO at CN Bio, said the collaboration will accelerate the expansion of the company’s OOC solutions: “Pharmaron were the ideal partner for CN Bio as we look to accelerate the growth of our OOC solutions portfolio… by working closely together and leveraging the industry-leading expertise of each company, we can share resources that enable us to progress new, innovative solutions from concept to global market deployment more effectively than ever before.”

Dr Tomasz Kostrzewski, CSO at CN Bio, highlighted the broader relevance of the project, referencing regulatory shifts: “Our platform is best placed to serve current market gaps including testing for immune-mediated organ damage… Together we can expedite this key development in line with global momentum for more ethical advancements that reduce costs and improve human health.”

Pharmaron’s CSO, Dr Hua Yang, commented on the value of OOC for translational research, stating: “We are pleased to collaborate with CN Bio to explore how this technology can add meaningful value to our partners’ development programs.”